DNA vaccination with the Mycobacterium marinum MMAR_4110 antigen inhibits reactivation of a latent mycobacterial infection in the adult Zebrafish

Niskanen, Mirja; Myllymäki, Henna; Rämet, Mika

doi:10.1016/j.vaccine.2020.06.053

Cited by 2 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Niskanen et al utilized low‐dose dexamethasone to reactivate LTBI zebrafish, detecting genes associated with Mm reactivation under in vitro anaerobic conditions. They identified the MMAR_4110 gene (corresponding to aldehyde dehydrogenase in Mm ) as effective in inhibiting LTBI reactivation, suggesting its potential as a TB vaccine antigen (Niskanen et al, 2020). Despite the distant relation between zebrafish and humans, and differences in LTBI immune mechanisms, the zebrafish LTBI model remains advantageous in the early‐stage screening of TB vaccine candidates due to its ease of operation and low cost.…”

Section: Vaccine Development Focus On Ltbimentioning

confidence: 99%

Advances in understanding immune homeostasis in latent tuberculosis infection

Niu,

Wang,

Luo

et al. 2024

WIREs Mechanisms of Disease

View full text Add to dashboard Cite

Nearly one‐fourth of the global population is infected by Mycobacterium tuberculosis (Mtb), and approximately 90%–95% remain asymptomatic as latent tuberculosis infection (LTBI), an estimated 5%–10% of those with latent infections will eventually progress to active tuberculosis (ATB). Although it is widely accepted that LTBI transitioning to ATB results from a disruption of host immune balance and a weakening of protective immune responses, the exact underlying immunological mechanisms that promote this conversion are not well characterized. Thus, it is difficult to accurately predict tuberculosis (TB) progression in advance, leaving the LTBI population as a significant threat to TB prevention and control. This article systematically explores three aspects related to the immunoregulatory mechanisms and translational research about LTBI: (1) the distinct immunocytological characteristics of LTBI and ATB, (2) LTBI diagnostic markers discovery related to host anti‐TB immunity and metabolic pathways, and (3) vaccine development focus on LTBI.This article is categorized under: Infectious Diseases > Molecular and Cellular Physiology Infectious Diseases > Genetics/Genomics/Epigenetics Immune System Diseases > Genetics/Genomics/Epigenetics

show abstract

Section: Vaccine Development Focus On Ltbimentioning

confidence: 99%

Advances in understanding immune homeostasis in latent tuberculosis infection

Niu,

Wang,

Luo

et al. 2024

WIREs Mechanisms of Disease

View full text Add to dashboard Cite

show abstract

“…Thus, this study identified two novel antigen candidates and provided support for the use of zebrafish to investigate TB vaccines that prevent reactivation of a latent infection. In a recent study by Niskanen et al (2020), an in vitro model for M. marinum latency and reactivation was used to identify mycobacterial genes specifically expressed during reactivation. When seven of these were tested as vaccine antigens, MMAR_4110 was shown to be protective against the reactivation of M. marinum infection in zebrafish (Niskanen et al, 2020).…”

Section: Immune Responsementioning

confidence: 99%

“…In a recent study by Niskanen et al (2020), an in vitro model for M. marinum latency and reactivation was used to identify mycobacterial genes specifically expressed during reactivation. When seven of these were tested as vaccine antigens, MMAR_4110 was shown to be protective against the reactivation of M. marinum infection in zebrafish (Niskanen et al, 2020). Although MMAR_4110, an aldehyde dehydrogenase, does not have a clear homologue in Mtb, the results suggest that the alcohol hydrogenases of Mtb could be potential target antigens for vaccine development.…”

Section: Immune Responsementioning

confidence: 99%

Integrating fish models in tuberculosis vaccine development

Saralahti

Uusi-Mäkelä

Niskanen

et al. 2020

Disease Models &Amp; Mechanisms

Self Cite

View full text Add to dashboard Cite

Tuberculosis is a chronic infection by Mycobacterium tuberculosis that results in over 1.5 million deaths worldwide each year. Currently, there is only one vaccine against tuberculosis, the Bacillus Calmette–Guérin (BCG) vaccine. Despite widespread vaccination programmes, over 10 million new M. tuberculosis infections are diagnosed yearly, with almost half a million cases caused by antibiotic-resistant strains. Novel vaccination strategies concentrate mainly on replacing BCG or boosting its efficacy and depend on animal models that accurately recapitulate the human disease. However, efforts to produce new vaccines against an M. tuberculosis infection have encountered several challenges, including the complexity of M. tuberculosis pathogenesis and limited knowledge of the protective immune responses. The preclinical evaluation of novel tuberculosis vaccine candidates is also hampered by the lack of an appropriate animal model that could accurately predict the protective effect of vaccines in humans. Here, we review the role of zebrafish (Danio rerio) and other fish models in the development of novel vaccines against tuberculosis and discuss how these models complement the more traditional mammalian models of tuberculosis.

show abstract

DNA vaccination with the Mycobacterium marinum MMAR_4110 antigen inhibits reactivation of a latent mycobacterial infection in the adult Zebrafish

Cited by 2 publications

References 44 publications

Advances in understanding immune homeostasis in latent tuberculosis infection

Advances in understanding immune homeostasis in latent tuberculosis infection

Integrating fish models in tuberculosis vaccine development

Contact Info

Product

Resources

About